Welcome members and clients of OMMP PIF. Due to increased costs, our website has moved to this server, Thanks go to our Friend and colleague, Wired57, for making this possible. If you have any questions or concerns, please start a new topic in 
Thank you 
10-28-2013, 08:15 PM
Endocannabinoids can treat Anorexia, & Bulimia.
![[Image: warlock-regular-seeds-magus-genetics-%25...2081-p.jpg]](http://www.headsite.com/ekmps/shops/hstrading/images/warlock-regular-seeds-magus-genetics-%255B5%255D-2081-p.jpg)
A new report in Biological Psychiatry suggests that deficits in endocannabinoid function may contribute to anorexia nervosa, and bulimia.
Endocannabinoids are substances made by the brain that affect brain function and chemistry in ways that resemble the effects of cannabis derivatives, including marijuana and hashish. These endocannabinoids are well known to increase appetite, i.e. to cause the munchies. Thus, it makes sense that deficits in this brain system would be associated with reduced appetite.
Researchers measured the status of the endocannabinoid system indirectly by determining whether there was an increase or decrease in the density of endocannabinoid receptors, called the CB1 receptor, in several brain regions using positron emission tomography, or PET, imaging. They compared these densities in women with anorexia or bulimia with those of healthy women.
They found global increases in ligand binding to CB1 receptors in the brains of women with anorexia nervosa. This finding is consistent with a compensatory process engaged by deficits in endocannabinoid levels or reduced CB1 receptor function.
CB1R availability was also increased in the insula in both anorexia and bulimia patients. The insula is a region that integrates body perception, gustatory information, reward and emotion, functions known to be disturbed in these patients, explained Dr. Koen Van Laere, the studys lead author.
The role of endocannabinoids in appetite control is clearly important. These new data point to important connections between this system and eating disorders, added Dr. John Krystal, Editor of Biological Psychiatry.
Additional research is now needed to establish whether the observed changes are caused by the disease or whether these are neurochemical alterations that serve as risk factors for developing an eating disorder.
Furthermore, since very few effective treatments exist for these disorders, these data indicate that the endocannabinoid system may be a potential new target for developing drugs to treat eating disorders. Such new therapies are currently being investigated in animal models.
Article Source: News Medical
Picture Source: Head Site
A new report in Biological Psychiatry suggests that deficits in endocannabinoid function may contribute to anorexia nervosa, and bulimia.
Endocannabinoids are substances made by the brain that affect brain function and chemistry in ways that resemble the effects of cannabis derivatives, including marijuana and hashish. These endocannabinoids are well known to increase appetite, i.e. to cause the munchies. Thus, it makes sense that deficits in this brain system would be associated with reduced appetite.
Researchers measured the status of the endocannabinoid system indirectly by determining whether there was an increase or decrease in the density of endocannabinoid receptors, called the CB1 receptor, in several brain regions using positron emission tomography, or PET, imaging. They compared these densities in women with anorexia or bulimia with those of healthy women.
They found global increases in ligand binding to CB1 receptors in the brains of women with anorexia nervosa. This finding is consistent with a compensatory process engaged by deficits in endocannabinoid levels or reduced CB1 receptor function.
CB1R availability was also increased in the insula in both anorexia and bulimia patients. The insula is a region that integrates body perception, gustatory information, reward and emotion, functions known to be disturbed in these patients, explained Dr. Koen Van Laere, the studys lead author.
The role of endocannabinoids in appetite control is clearly important. These new data point to important connections between this system and eating disorders, added Dr. John Krystal, Editor of Biological Psychiatry.
Additional research is now needed to establish whether the observed changes are caused by the disease or whether these are neurochemical alterations that serve as risk factors for developing an eating disorder.
Furthermore, since very few effective treatments exist for these disorders, these data indicate that the endocannabinoid system may be a potential new target for developing drugs to treat eating disorders. Such new therapies are currently being investigated in animal models.
Article Source: News Medical
Picture Source: Head Site